趋化因子 CXCL12，也称为基质细胞衍生因子 1 (SDF1)，已成为驱动癌症进展的复杂分子网络中的关键调节因子。作为肿瘤微环境的影响因素，CXCL12发挥着多方面的作用，超越了其作为诱导侵袭和转移的趋化因子的传统作用。事实上，CXCL12 已被赋予与上皮间质转化、癌细胞干性、血管生成和免疫抑制相关的功能，所有这些目前都被视为有助于其他癌症标志中的“转移级联”的特殊生物程序。它与其同源受体 CXCR4 相互作用，引发一系列事件，不仅塑造肿瘤细胞的转移潜力，而且定义了支持转移定植的次级器官内的生态位。鉴于 CXCL12 在转移级联中的深远影响，了解其机制基础对于有针对性地消除转移过程中的限速步骤至关重要。本综述旨在全面概述有关 CXCL12 在癌症转移中的作用的当前知识，特别是其分子相互作用，使其作为治疗靶点的潜力合理化。版权所有 © 2023 作者。由爱思唯尔有限公司出版。保留所有权利。

The chemokine CXCL12, also known as stromal cell-derived factor 1 (SDF1), has emerged as a pivotal regulator in the intricate molecular networks driving cancer progression. As an influential factor in the tumor microenvironment, CXCL12 plays a multifaceted role that spans beyond its traditional role as a chemokine inducing invasion and metastasis. Indeed, CXCL12 has been assigned functions related to epithelial-to-mesenchymal transition, cancer cell stemness, angiogenesis, and immunosuppression, all of which are currently viewed as specialized biological programs contributing to the "metastatic cascade" among other cancer hallmarks. Its interaction with its cognate receptor, CXCR4, initiates a cascade of events that not only shapes the metastatic potential of tumor cells but also defines the niches within the secondary organs that support metastatic colonization. Given the profound implications of CXCL12 in the metastatic cascade, understanding its mechanistic underpinnings is of paramount importance for the targeted elimination of rate-limiting steps in the metastatic process. This review aims to provide a comprehensive overview of the current knowledge surrounding the role of CXCL12 in cancer metastasis, especially its molecular interactions rationalizing its potential as a therapeutic target.Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.